Harmony Biosciences Holdings, Inc. (HRMY) stock
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)
Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –
Harmony Biosciences total assets
Total assets on the balance sheet at the end of each period.
Harmony Biosciences's total assets was $1.37B at Jun 30, 2026. For fiscal 2025 it was $1.27B, up 27.3% from the year before. The highest annual figure on record is $1.27B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.27B | +27.3% |
| FY2024 | Dec 31, 2024 | $999.20M | +23.1% |
| FY2023 | Dec 31, 2023 | $811.45M | +20.4% |
| FY2022 | Dec 31, 2022 | $673.87M | +55.5% |
| FY2021 | Dec 31, 2021 | $433.44M | +1.5% |
| FY2020 | Dec 31, 2020 | $427.07M | +300.2% |
| FY2019 | Dec 31, 2019 | $106.70M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.37B | +23.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.27B | +20.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.27B | +27.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.21B | +30.2% |
| Q2 FY2025 | Jun 30, 2025 | $1.11B | +29.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.06B | +24.6% |
| Q4 FY2024 | Dec 31, 2024 | $999.20M | +23.1% |
| Q3 FY2024 | Sep 30, 2024 | $928.14M | +19.3% |
| Q2 FY2024 | Jun 30, 2024 | $858.38M | +12.9% |
| Q1 FY2024 | Mar 31, 2024 | $846.99M | +18.4% |
| Q4 FY2023 | Dec 31, 2023 | $811.45M | +20.4% |
| Q3 FY2023 | Sep 30, 2023 | $777.77M | +20.9% |
| Q2 FY2023 | Jun 30, 2023 | $760.18M | +50.5% |
| Q1 FY2023 | Mar 31, 2023 | $715.09M | +54.1% |
| Q4 FY2022 | Dec 31, 2022 | $673.87M | +55.5% |
| Q3 FY2022 | Sep 30, 2022 | $643.46M | +64.5% |
| Q2 FY2022 | Jun 30, 2022 | $505.03M | +40.4% |
| Q1 FY2022 | Mar 31, 2022 | $464.01M | +37.6% |
| Q4 FY2021 | Dec 31, 2021 | $433.44M | +1.5% |
| Q3 FY2021 | Sep 30, 2021 | $391.09M | +22.2% |
| Q2 FY2021 | Jun 30, 2021 | $359.70M | +237.1% |
| Q1 FY2021 | Mar 31, 2021 | $337.25M | – |
| Q4 FY2020 | Dec 31, 2020 | $427.07M | – |
| Q3 FY2020 | Sep 30, 2020 | $320.07M | – |
| Q4 FY2019 | Dec 31, 2019 | $106.70M | – |
See a number that looks wrong?